Finn RS, Crown J, Lang I, et al. Overall survival results from the randomized phase II study of palbociclib (P) in combination with letrozole (L) vs letrozole alone for frontline treatment of ER+/HER2– advanced breast cancer (PALOMA-1; TRIO-18). J Clin Oncol. 35, 2017 (suppl; abstr 1001).
Adjuvant sorafenib na RFA verbetert prognose van HCC-patiënten
aug 2022 | Maag-darm-leveroncologie